Document is current
Any future updates will be listed below
-
Authors
Yuan, Kai https://orcid.org/0000-0002-8460-6581
Longchamps, Ryan J.
Pardiñas, Antonio F. https://orcid.org/0000-0001-6845-7590
Yu, Mingrui https://orcid.org/0000-0002-2749-0690
Chen, Tzu-Ting https://orcid.org/0000-0001-5669-9066
Lin, Shu-Chin
Chen, Yu
Lam, Max https://orcid.org/0000-0002-4256-7844
Liu, Ruize
Xia, Yan
Guo, Zhenglin
Shi, Wenzhao
Shen, Chengguo
,
Daly, Mark J. https://orcid.org/0000-0002-0949-8752
Neale, Benjamin M. https://orcid.org/0000-0003-1513-6077
Feng, Yen-Chen A.
Lin, Yen-Feng https://orcid.org/0000-0003-3017-6026
Chen, Chia-Yen https://orcid.org/0000-0001-9548-5597
O’Donovan, Michael C. https://orcid.org/0000-0001-7073-2379
Ge, Tian https://orcid.org/0000-0003-4785-4444
Huang, Hailiang https://orcid.org/0000-0003-1461-5762
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH130675)
- License Information
-
More Information
Article History
Received: 10 January 2023
Accepted: 15 July 2024
First Online: 26 August 2024
Competing interests
: W.S. and C.S. are employees of Digital Health China Technologies. M.J.D. is a founder of Maze Therapeutics. B.M.N. is a member of the scientific advisory board at Deep Genomics and Neumora. C.-Y.C. is an employee of Biogen. R.J.L. is an employee of Ionis Pharmaceuticals. M.C.O. was supported by a collaborative research grant from Takeda Pharmaceuticals for a project unrelated to work presented in this article. Takeda played no part in the conception, design, implementation or interpretation of this study. H.H. received consultancy fees from Ono Pharmaceutical and an honorarium from Xian Janssen Pharmaceutical. The other authors declare no competing interests.
